Bolivian hemorrhagic fever has had no legitimate treatment options, and because of the high mortality rate, there is an immediate need for therapeutics and vaccines which are well designed. We at our company are fully dedicated towards the cause of developing this medicine with the help of multiple pioneering scientific methods and strong preclinical services.
Overview of Bolivian Hemorrhagic Fever
Bolivian hemorrhagic fever (BHF) is an acute illness and has a high mortality rate. It is mostly caused by the machupo and chapara viruses. It is a zoonotic disease that spreads through contact with the excretions or secretions from a range of wild rodents such as the Callomys Callosus. BHF includes three phases; prodromal stage includes general symptoms such as fever and myalgia. Survivors introduce the convalescent stage after the first phase, but bleeding seems to extend all throughout the second phase which is considered deadly.
Fig.1 Geographic distribution of Callomys callosus, Machupo virus (MACV), and Chapare virus (CHAPV) human cases in Bolivian territory. (Silva-Ramos C. R., et al., 2021)
Vaccine Development for Bolivian Hemorrhagic Fever
Multi-Epitope-Based Vaccines
Novel multi-epitope-based roducts which could serve as potent vaccines against BHF were developed and have been mentioned in recent scientific literature. Such vaccines are constructed with the aid of immunoinformatics techniques and are focused on B and T cell epitopes of the viral nucleocapsid protein. The epitopes are chosen on the bases of antigenicity and are non-allergenic, hence guaranteeing a robust immune response with no side effects.
Reverse Vaccinology Approach
The approach of reverse vaccinology has greatly aided in the production of the BHF vaccines. This approach consists of the first in silico scanning of the viral DNA to locate potential antigenic proteins and then a laboratory analysis for validating those candidates. This strategy has enhanced the identification of the previously unknown epitope and broad tailored vaccine development which is a new avenue for therapeutic against BHF.
Therapeutics Development for Bolivian Hemorrhagic Fever
The development of antiviral drugs specifically for BHF has been met with adversity, because there are no approved therapeutic drugs, ribavirin is one of the broad-spectrum antivirals that was attempted to be used recently, and while treating BHF some positive results were noted. The direction is now to improve these therapies and minimize their side effects and do a lot of clinical trials in order to establish drug safety and efficacy profiles.
The production of monoclonal antibodies for selective viral elements could be a valuable therapeutic option. These antibodies can neutralize the agent of the disease, and thus it can lessen the virus's prognosis. Our company has the capabilities to develop innovative BHF therapies. You can click on the link below to learn about our one-stop therapy development services.
Our Services
We approach BHF vaccine and therapy development with all protocols in consideration and as a whole. To assure indicators and agents of the vaccine are safe to use and dependable, modern techniques are utilized so that innovation and science are further emphasized.
- Guinea Pig Models: the Machupo virus-Chicava strain is administered via aerosol challenge to guinea pigs.
- Rhesus Monkey MACV Infection Models
- Cynomolgus Macaque MACV Infection Models
Our preclinical research services are designed to support the development of BHF vaccines and therapeutics from initial discovery through to late-stage preclinical evaluation. If you are interested in our services, please feel free to contact us.
References
- Silva-Ramos, Carlos Ramiro, et al. "Bolivian hemorrhagic fever: a narrative review." Travel Medicine and Infectious Disease 40 (2021): 102001.
- Naveed, Muhammad, et al. "Immunoinformatics approach to design multi-epitope-based vaccine against machupo virus taking viral nucleocapsid as a potential candidate." Vaccines 10.10 (2022): 1732.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
